Which feature best distinguishes ACE inhibitors from angiotensin II receptor blockers (ARBs) in terms of teratogenic risk during pregnancy?

Explanation

## Distinguishing ACE Inhibitors from ARBs in Pregnancy ### Teratogenic Risk Profile **Key Point:** Among the options given, Option A best distinguishes the two drug classes: ACE inhibitors have established teratogenicity across **all three trimesters**, whereas ARBs — while also contraindicated throughout pregnancy per most current guidelines — lack the same level of confirmed first-trimester teratogenicity data as ACE inhibitors. > **Important caveat:** "Safer in the first trimester" does NOT mean ARBs are safe — it means first-trimester ARB teratogenicity is less well-established compared to ACE inhibitors. Both classes should be avoided throughout pregnancy whenever possible. ### Mechanism of Fetal Injury Both drug classes block the renin-angiotensin-aldosterone system (RAAS), which is critical for fetal renal perfusion, urine production, and amniotic fluid homeostasis. Disruption leads to: - **Renal tubular dysgenesis / renal dysgenesis** - **Oligohydramnios** → limb contractures, pulmonary hypoplasia, craniofacial deformities (Potter sequence) - **IUGR and neonatal renal failure** | Feature | ACE Inhibitors | ARBs | |---------|---|---| | **First Trimester** | Contraindicated — established cardiac & renal teratogenicity (Cooper et al., NEJM 2006) | Contraindicated per guidelines, but first-trimester teratogenicity less clearly established | | **Second/Third Trimester** | Absolutely contraindicated — renal dysgenesis, oligohydramnios | Absolutely contraindicated — same fetopathic effects as ACE inhibitors | | **FDA Category (legacy)** | D (2nd/3rd trimester); C (1st trimester, later revised to D) | D (2nd/3rd trimester); C (1st trimester, later revised to D) | | **Key distinction** | Teratogenicity confirmed in ALL trimesters | Teratogenicity confirmed in 2nd/3rd; 1st trimester data less robust | ### Why the Other Options Are Wrong - **Option B:** Incorrect — both ACE inhibitors and ARBs can cause renal dysgenesis in the second and third trimesters; neither is restricted to only one trimester. - **Option C:** Incorrect — ARBs have been studied in pregnancy; the issue is not absence of data but rather that their first-trimester risk profile is less definitively established than ACE inhibitors. - **Option D:** Incorrect — both classes cause **oligohydramnios** (not polyhydramnios) due to fetal renal suppression; they are not distinguished by opposite amniotic fluid effects. ### Clinical Pearl Women of childbearing age on ACE inhibitors or ARBs must receive preconception counseling. Upon confirmed pregnancy, both classes should be discontinued immediately and switched to safer antihypertensives: **methyldopa, labetalol, or nifedipine** are preferred. The key high-yield distinction for NEET PG is that ACE inhibitors carry proven teratogenic risk in the first trimester (cardiac malformations, renal anomalies), while ARBs share the same second/third trimester fetopathic profile but have less definitive first-trimester teratogenicity data. **High-Yield:** ACE inhibitors = contraindicated all 3 trimesters (established). ARBs = contraindicated all 3 trimesters (established for 2nd/3rd; less proven but still avoided in 1st). [cite: KD Tripathi 8e Ch 21; Cooper et al., NEJM 2006; Briggs, Freeman & Towers — Drugs in Pregnancy and Lactation, 11e]